Introduction {#section1-2325958218759208}
============

HIV is a chronic infection manageable with different regimens of antiretroviral drugs self-administered daily in pill form. Older regimens are still in use, but switching to newer and less-constraining ones (in terms of side effects and number of pills) is considered a means of improving patients' adherence.^[@bibr1-2325958218759208],[@bibr2-2325958218759208]^ "Adherence," or the extent to which a person's medication uptake corresponds with their clinician's indications,^[@bibr3-2325958218759208]^ is a major concern in HIV clinical practice.^[@bibr4-2325958218759208][@bibr5-2325958218759208]--[@bibr6-2325958218759208]^ It is a condition for therapeutic success, particularly, a high CD4 count and an undetectable viral load, which reduces risks of disease progression, development of resistance, and secondary transmission.^[@bibr7-2325958218759208],[@bibr8-2325958218759208]^ A meta-analysis suggests that almost half (45%) of HIV-positive patients in North America have suboptimal adherence (below 80%-100%, depending on the study).^[@bibr9-2325958218759208]^

Antiretroviral treatment (ART) adherence is complex and difficult to measure. Adherence barriers vary between patients and over time.^[@bibr10-2325958218759208][@bibr11-2325958218759208][@bibr12-2325958218759208]--[@bibr13-2325958218759208]^ Moreover, studies demonstrate that clinicians' estimations of patients' adherence can be erroneous^[@bibr14-2325958218759208],[@bibr15-2325958218759208]^ and that ART adherence barriers are not always adequately discussed during clinical consultations.^[@bibr16-2325958218759208][@bibr17-2325958218759208]--[@bibr18-2325958218759208]^ Patients' biomedical outcomes give only a partial assessment of adherence^[@bibr19-2325958218759208]^ and supply no information on patients' subjective experiences of ART-taking.

Given this complexity, a review of interpretative models of adherence in chronic conditions concluded that adherence interventions should include analyses of patients' perceptions.^[@bibr10-2325958218759208]^ "Patients' perceptions" refer here to patients' cognitive frameworks to make sense of their medical condition and treatments.^[@bibr20-2325958218759208]^ Patients build these frameworks based on received information, individual experiences, and beliefs. They may differ in important ways from clinicians' frameworks^[@bibr21-2325958218759208]^ and influence how patients manage their treatment adherence.^[@bibr20-2325958218759208],[@bibr22-2325958218759208]^ For instance, the association between HIV-positive patients' negative perception of ART and low adherence has been demonstrated.^[@bibr23-2325958218759208]^ In the investigation of patient's perceptions in relation to adherence, a growing literature analyzes their subjective experiences of time.^[@bibr24-2325958218759208]^

In HIV, few studies have examined how temporality affects patients' perceptions of adherence barriers or have done so while focusing on specific dimensions of temporality, such as biographical disruptions^[@bibr25-2325958218759208]^ or dailyART-taking.^[@bibr1-2325958218759208]^ A recent narrative review highlighted the need for analyses accounting for different patients' experiences of time.^[@bibr26-2325958218759208]^ This analysis could shed light on the meanings, for HIV-positive patients, of past events, ART-taking routines, and their future, and help improve adherence interventions. Our objective is thus to explore how time is experienced in patients' perceptions of their adherence barriers.

Methods {#section2-2325958218759208}
=======

Context of the Study {#section3-2325958218759208}
--------------------

Data were collected in the context of the Interference-Score (I-Score) Study, a 2-year multisited Canada/France project that aims to develop and validate a patient-reported outcome measure on ART adherence barriers for use in HIV care. A patient engagement project was initiated to integrate patients' perspective in the I-Score Study. It consists of a Montreal-based group of 10 HIV-positive patients, the I-Score Consulting Team (henceforth, the Team),^[@bibr27-2325958218759208]^ which meets periodically to discuss progress on the study. This article presents the results of the first research activity conducted with the Team. We obtained approval for the present study from the research ethics board of the McGill University Health Centre's Research Institute, in Montreal, Canada.

Design and Conceptual Framework {#section4-2325958218759208}
-------------------------------

This exploratory study draws on the concept of life course^[@bibr28-2325958218759208],[@bibr29-2325958218759208]^ which is based on specific assumptions: one's life events take place at specific moments, sometimes take time to fully unfold, and are influenced by those of others.^[@bibr28-2325958218759208],[@bibr29-2325958218759208]^ It promises an understanding of complex phenomena that situates individual and dynamic experiences in relation to broader influences.^[@bibr30-2325958218759208]^ It grounds descriptive observations and analyses in theories on people's everyday lives^[@bibr1-2325958218759208],[@bibr31-2325958218759208]^ and biographical disruptions.^[@bibr32-2325958218759208]^ This framework has been employed in sociological studies of medical issues focused on chronic patients' "real life" experiences.^[@bibr24-2325958218759208],[@bibr26-2325958218759208],[@bibr32-2325958218759208],[@bibr33-2325958218759208]^

Sample, Data Collection, and Analysis {#section5-2325958218759208}
-------------------------------------

Participants were mainly recruited from the Team, constituted using a maximum variation sampling technique, a type of purposive sampling aimed at capturing a wide range of perspectives relating to a topic.^[@bibr34-2325958218759208]^ We recruited one additional individual for each focus group, to compensate for any cancellations or no-shows.^[@bibr35-2325958218759208]^ A total of 11 participants took part in 2 sex-specific focus groups in November 2015 led by I.T. and observed by D.L. and A.L. Focus groups lasted 120 and 135 minutes, respectively. They employed a semistructured format including an introductory round table discussion and open-ended questions on ART adherence barriers participants would like to report to their clinician and how they would like to report them. Participants were compensated (CAN\$50).

Focus groups were audiotaped and transcribed. D.L. entered the transcriptions into the software Altas.ti (version 7.5.10, 1993-2016, by ATLAS.ti GmbH) and analyzed the data following the first 5 stages of the Grounded Theory method (coding, categorizing, association, integration, and modeling).^[@bibr36-2325958218759208],[@bibr37-2325958218759208]^ These concurrent stages can inductively generate descriptions of "real life" dynamics and, by deconstructing and reconstructing the data, identify essential content, abstract concepts, and models.^[@bibr36-2325958218759208]^ Analyses centered on all focus group content relevant to participants' perceived adherence barriers. To improve the reliability of results, the coding grid employed was discussed with coauthors.

In order to validate our modeling,^[@bibr38-2325958218759208]^ we conducted a third audio-recorded focus group to discuss the preliminary analyses with the Team, facilitated by D.L. (n = 8, 140 minutes). This focus group was held within one of the Team's regular meetings. It thus included 1 participant (P12, a female Team member) who had been invited but could not participate in the first focus group. During this third focus group, D.L. asked participants to consider and explain in their own words the main categories developed and to confirm or qualify key statements of the model.^[@bibr38-2325958218759208]^ This discussion was transcribed and integrated into the analysis, adjusting the coding grid as necessary. This exercise sought to validate our analysis, avoid biases, increase the soundness of our interpretations and conclusions in relation to the data,^[@bibr39-2325958218759208]^ and refine our understanding of the categories and their interrelations.^[@bibr40-2325958218759208]^

Results {#section6-2325958218759208}
=======

[Table 1](#table1-2325958218759208){ref-type="table"} presents participants' characteristics. Our analysis identified 3 temporal categories manifest in participants' perceptions of adherence barriers: (1) imprinting, (2) domino effects, and (3) future shadowing. An essential theme, weathering, ran through these categories. We illustrate these temporal categories and the overarching theme in [Table 2](#table2-2325958218759208){ref-type="table"}.

###### 

Characteristics of Participants in Each Focus Group, at the Exploratory and Validation Phases of Data Collection.

![](10.1177_2325958218759208-table1)

  Participant   Age Group (in Years)   Group                                    Number of Years on ART   Exploratory Phase   Validation Phase   
  ------------- ---------------------- ---------------------------------------- ------------------------ ------------------- ------------------ ---
  P1            20-29                  African woman self-identified as queer   Over 10 years            x                                      
  P2            50-59                  African WSM                              Over 10 years            x                                      x
  P3            50-59                  White WSM                                1-3 years                x                                      
  P4            50-59                  Latin American WSM                       Over 10 years            x                                      
  P5            40-49                  African WSM                              Over 10 years            x                                      x
  P6            30-39                  White MSM                                3-6 years                                    x                  x
  P7            60-69                  African MSW                              Over 10 years                                x                  x
  P8            30-39                  White MSM                                Over 10 years                                x                  x
  P9            50-59                  White MSW                                Over 10 years                                x                  
  P10           30-39                  European White MSM                       Less than 1 year                             x                  x
  P11           50-59                  White MSM                                Over 10 years                                x                  x
  P12           50-59                  White WSM                                Over 10 years                                                   x

Abbreviations: ART, antiretroviral treatment; MSM, man who has sex with men; MSW, man who has sex with women; WSM, woman who has sex with men.

###### 

Illustration of the Participants' ART Adherence Barriers in Relation to the Temporal Categories.

![](10.1177_2325958218759208-table2)

  Temporal Category 1: Imprinting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Example 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  P11: "I was diagnosed in the winter of 83-84. My doctor told me my chances of survival, with the first cocktails, were almost nothing. (...) If I've been here this long, I must have been doing something right.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       **Imprint** **Unpleasant and emotionally charged event: Survival despite the threat of death due to a lack of access to efficient ART for a long period after diagnosis**
  Today, it's not enough for me just to take the drug, the right dose, at the right time. No, I'd be dead if I did just that. So many people who just took the drugs, relying on the drugs like a crutch, are dead.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Impact on perception of ART Perception that only taking ART is not enough to maintain health and that doing so may be hazardous to one's health.
  I did my own research; I'm very aggressive when it comes to my health, very proactive, it's my responsibility. The doctor's there to help you with the diagnostic, but the first question I asked was what can I do? P1: "What interests me as a patient \[who had limited access to ART for years before I learned my diagnosis\] is to understand how I survived before I was officially HIV positive. What are the other drugs? Or, my aunts who raised me, what did they give me on the nutrition side? What kept me healthy while being HIV-positive? (...) I ate well. Do I need another advice like doing sports to simulate my immunity? I would like (the clinician) to inform me on natural products that we sometimes look for elsewhere."   Impact on ART adherence Proactive approach where adherence becomes one practice among others (researching, eating well, exercising, etc) to maintain health and manage HIV combined with an interest in alternative medicine
  Example 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  P2: "In the past, I saw people with lipodystrophy. It was scary. When I began treatment, I thought: I will begin to be like this. (...)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 **Imprint** **Unpleasant and emotionally charged event: Seeing HIV-infected persons with severe lipodystrophy**
  When I received my diagnosis, I thought about these people with HIV I had seen: they did not look good. I could see they were sick. Nowadays, there are no signs. People look healthy. But I put myself in this image. I thought: 'This is what will happen to me.' People will reject me if I start to lose weight. If I look sick, they will be afraid.(...)                                                                                                                                                                                                                                                                                                                                                                                          Impact on perception of ART While recognizing that the side effects of newer ART regimens have changed, an association between ART and lipodystrophy persists, with the fear that ART will make one visibly sick, leading to social exclusion
  I would skip doses: 'If I do not take it every day, maybe the effects will be less strong. It will not show as much'."                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Impact on ART adherence Skipped doses to limit lipodystrophy
  Example 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  P9: "I noticed my body odor changed with a drug. It is not really important, but when I have sexual intercourse, it is obvious for my partner. (...)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    **Imprint** **Unpleasant and emotionally charged event: Side effect (odor) that impacts one's sex life**
  It's the first thing I think about when I switch drugs: 'Ah! It will maybe change my smell.'                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Impact on perception of ART View that other ART regimens may have a similar effect
  We'll take the drug anyway. At the end of the day, I'm still alive. It doesn't matter if I stink like Pepe le Pew."                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Impact on ART adherence Adherence for survival, despite possible side effects

  Temporal Category 2: Domino Effects                                                                                                                                                                                                                                                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Example 4                                                                                                                                                                                                                                                                                 
  P2: "I was on a drug. When you took it, you fell asleep. I worked night shifts then. It was complicated to take it: working in health, I couldn't sleep. Sometimes, I would agree with the person working with me and I could take a break. I would take my med and sleep on the break.   Dormant barriers (shift work in the health field and a side effect---drowsiness) that can usually be accommodated
  But if I worked with another person who wasn't used to it, it was a problem.                                                                                                                                                                                                              **Domino effect** **Change in coworker reactivates adherence barriers of shift work and side effect**
  I was obliged to skip a dose."                                                                                                                                                                                                                                                            Impact on ART adherence Skipped doses
  Example 5                                                                                                                                                                                                                                                                                 
  P8: "Before I was on welfare.                                                                                                                                                                                                                                                             Welfare provides full coverage for medication
  I went back to school and lost welfare \[because I got student loans\], so I was obliged to pay for my meds. I was broke, so I either ate or I took my meds.                                                                                                                              **Domino effect** **Return to school precipitates loss of welfare and change in medication coverage status. Income remains low, leading to difficult choices between basic necessities and ART**
  I decided to eat and I didn't take my meds for a year."                                                                                                                                                                                                                                   Impact on ART adherence Treatment interruption
  Example 6                                                                                                                                                                                                                                                                                 
  P5: "I took iron supplements, but they changed my med.                                                                                                                                                                                                                                    ART regimen switch during treatment for other health condition (anemia)
  There is an interaction between the two. I cannot take the iron supplement. So it changes my habits. I have to eat iron-rich food and it requires more follow-up. (...)                                                                                                                   **Domino effect** **Interactions between medications require new eating habits and more follow-up, which complicate health management**
  \[Anybody could need iron.\] The problem is the drug for HIV. It's the iron supplement I should take!"                                                                                                                                                                                    Impact on perception of ART ART is seen as *the* problem
  Example 7                                                                                                                                                                                                                                                                                 
  P2: "I really wanted to work.                                                                                                                                                                                                                                                             Desire to find employment
  I found a job in a hospital. The first day of the training, they took our blood. They saw I was HIV-positive. I was the only one they dismissed. \[I was discriminated against.\]                                                                                                         **Domino effect 1** **Finding a job led to a health screening and the person's subsequent dismissal**
  So in my next jobs, I worked in the private sector, where I was paid half the salary, because I didn't want them to see again. I prefer to be underpaid, at the minimum wage, where they won't ask me questions, where there is no health insurance, with no health exams.                **Domino effect 2** **Felt discrimination (Domino effect 1) led to seeking employment in lower paid private sector to avoid health screening, resulting in reduced health coverage**
  And poverty exposes you (...) There were times I did not take (ART). Why? Because every month, I have to spend \$154. I do not have it, even if I look for it. So I say: 'Today, I do not take it' to make it last more days. These drugs are expensive'."                                Impact on ART adherence Consequent financial strain led to skipped doses to stretch the ART prescription

  Temporal Category 3: Future shadowing                                                                                                                                                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  Example 8                                                                                                                                                                               
  P8: "\[When taking ART,\] you shouldn't consider what will happen in more than 2 years because we don't know. (...) It's like the unknown.                                              **Future shadowing** **Difficulties in projecting oneself into the future**
  It's better to say: 'I'm lucky to be alive now' and take your meds one by one."                                                                                                         Impact on ART adherence Taking one dose at a time
  Example 9                                                                                                                                                                               
  P7: "We know these drugs are toxic and I talked about it with my doctor. He tells me that I will not die of AIDS. It will be a stroke, or the kidneys, the pancreas, or the arteries.   **Future shadowing** **Understanding that death will come from the long-term toxicity of ART**
  So we must take them and keep a positive way of thinking. (...) This is a concern for me."                                                                                              Impact on ART adherence Resignation to take ART despite concerns about this
  Example 10                                                                                                                                                                              
  P10: "The only barrier that kept me from accessing treatments was linked to my status here in Canada. We must get my meds through crooked paths.                                        Immigrant status precludes receiving coverage of ART, leading to precarious solutions to access ART
  As long as I haven't fixed my status as a foreigner, sooner or later, the access will be blocked. We can only postpone this barrier. It will come back."                                **Future shadowing** **Unless immigrant status is changed, this adherence barrier will likely return**

  Overarching Theme: Weathering                                                                                                                                                                                                                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------
  Example 11                                                                                                                                                                                                                                                                                                   
  P5: "It's not worth it with the side effects, let's say, with the money we can barely find, with life that goes wrong, with the relationships that don't go well.                                                                                                                                            **Weathering** **Accumulation over time of challenging life events associated with HIV and ART**
  It's all of that that does that adherence can lead us to drop treatment, and even to death."                                                                                                                                                                                                                 Impact on ART adherence Combined effect of the above can lead to abandoning ART with its associated impacts on health
  Example 12                                                                                                                                                                                                                                                                                                   
  P3: "You have a little problem that appears. They \[clinicians\] tell you: 'It may be due to the drug.' This puts a small weight on your back. Then, you do not feel good: 'Is it because I still take these drugs? It might also be because I feel lonely,' but the drugs might be the cause of that too.   **Weathering** **Growing burden of experiencing multiple symptoms and attempting to interpret their origin**
  All these problems become so heavy, you say: 'Why do I keep on taking this?'"                                                                                                                                                                                                                                Impact on perception of ART Utility of ART becomes questionable

Abbreviations: ART, antiretroviral treatment, The significance of boldface is to emphasize mechanisms of, respectively, imprinting, domino effects, future-shadowing, and weathering, in each of the examples.

Imprinting {#section7-2325958218759208}
----------

"Imprinting" refers to the processes by which unpleasant and emotionally charged ART- or HIV-related events etch persistent memories with long-lasting and significant impacts on perceptions of ART and, consequently, adherence. This occurred in participants who lived for an extended period of time with HIV either without ART or with limited access to it (Example 1) and participants who witnessed (Example 2) or had (Example 3) unpleasant ART-related experiences (eg, side effects, interactions between ART and treatments for other health conditions, discrimination).

Domino Effects {#section8-2325958218759208}
--------------

"Domino effects" denote chain reactions in personal (eg, moving to another province or country, finding a new partner), professional (eg, academic or professional career changes), and/or medical events (eg, an ART regimen switch, the appearance of another health condition) that can impact perceptions of ART and/or adherence. Domino effects can reactivate a previously dormant barrier (Example 4), a barrier experienced in the past. They can also lead patients to consider ART a lower priority (Example 5) or as potentially detrimental to their well-being (Example 6). Finally, they can impact patients' life choices which, in turn, can affect their behavior, contributing to adherence barriers (Example 7).

Future Shadowing {#section9-2325958218759208}
----------------

"Future shadowing" characterizes participants' concerns raised by the long-term ART-taking, which can impact perceptions of ART and/or adherence. These concerns include the difficulty of projecting themselves into the long term (Example 8), preoccupations for ART toxicity and long-term side effects (Example 9), and the anticipation of repeatedly facing similar barriers (Example 10).

Overarching Theme: The Weathering of Adherence {#section10-2325958218759208}
----------------------------------------------

Weathering refers here to the gradual erosion of patients' well-being or ability (Example 11) or resolve (Example 12) to adhere by impacting perceptions of ART and/or adherence. It is caused by an accumulation over time of ART-related concerns or episodes of managing adherence barriers that stem from the dynamics of imprinting, domino effects, and future shadowing.

Discussion {#section11-2325958218759208}
==========

Our analysis of focus groups conducted with HIV-positive patients revealed 3 temporalities and one theme relevant to patients' perceptions of adherence barriers. First, imprinting refers to a linear temporality in which unpleasant events have lasting impacts on adherence. Second, domino effects form a processual temporality in which barriers emerge from life circumstances. Third, future shadowing refers to a prospective temporality underlining patients' ambivalence toward life-long adherence. Like in other studies reporting on temporalities in chronic patients' perceptions,^[@bibr26-2325958218759208]^ temporal narratives "collide" in patients' accounts. An overarching theme, "weathering," related to participants' reports of gradually losing motivation and capacity for adherence, runs through these categories.

Similar metaphorical usages of these terms were found in other scientific publications. "Imprint" has been used in psychology and ethology to designate phase-sensitive unconscious learning processes,^[@bibr41-2325958218759208]^ to illustrate the impacts of experiences of care on patients' memory and perception of treatment,^[@bibr42-2325958218759208]^ and to refer to repercussions of sociopolitical conditions on how people define the HIV epidemic.^[@bibr43-2325958218759208]^ The "domino effect" metaphor has been used to highlight interactions between different dimensions of a health condition and its treatment.^[@bibr44-2325958218759208]^ The notion of "future shadowing" was inspired by that of a "dark future" which is used in a measure of pessimism.^[@bibr45-2325958218759208]^ Weathering refers to the breaking down of minerals due to contact with elements.^[@bibr46-2325958218759208]^ It has been used to refer to premature health deterioration due to adversity.^[@bibr47-2325958218759208]^ We chose these terms as they illustrated well the participants' temporal perceptions of adherence barriers.

Participants mentioned perceived barriers as diverse as side effects, meanings of life-long ART and of its costs, and discrimination. These barriers coincide with studies that show that nonadherence to ART is exacerbated by socioeconomic vulnerability,^[@bibr48-2325958218759208]^ age,^[@bibr49-2325958218759208],[@bibr50-2325958218759208]^ discrimination,^[@bibr51-2325958218759208]^ and ART characteristics (eg, number of doses, side effects).^[@bibr52-2325958218759208]^ Our results are coherent with an ART adherence model which presents adherence as a compromise between the conflicting demands of everyday life (including work demands, \[disrupted\] routines, and eating habits), side effects, depression, perceived ART effectiveness, and social support.^[@bibr53-2325958218759208]^ They also provide rationales for how patients may give differential meaning to a similar barrier depending on its temporal quality and highlight how adherence barriers can gain traction in patient perceptions to ultimately impact adherence. Moreover, we show that adherence barriers may stem from concerns for one's health or situation, for example, when one looks for alternative health practices, seeks to avoid discrimination, or faces financial difficulties.

Tentative implications for practice include the following points: (1) adherence should be recognized as a process, (2) perfect life-long adherence as a universal, "one-size-fits-all" objective is unrealistic, (3) adherence barriers must be considered in the context of each patient's particular circumstances, and (4) interventions should include regular assessments of patients' perceptions of adherence barriers and employ multidimensional tools that cover such elements as patient-reported barriers, values, perception of alternative health practices, significant life changes, and key moments of vulnerability, such as regimen switches. Indeed, the latter may jeopardize adherence by exposing patients to different side effects, indications, and costs.^[@bibr52-2325958218759208]^ These could help identify potential sources of imprinting, domino effects, or future shadowing.

The 2 focus groups give this study an exploratory status, relevant for the subsequent steps of the I-Score Study. Further research and a larger sample could lead to a more complete model of adherence and temporality that is transferable to different contexts. The focus groups' centering on adherence barriers may have emphasized negative aspects of ART at the expense of a more balanced perspective. We did not reach saturation with our analyses. However, rich data were collected from a diverse sample of people living with HIV and included a third focus group to maximize the analyses' trustworthiness. Moreover, our results indicate that inquiring about HIV-positive patients' temporal experiences of adherence may represent an interesting and relevant avenue for further research. The strength and originality of this study lie in its articulation of adherence barriers within a temporal framework that could prove useful for clinical evaluations.
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